Blockchain Registration Transaction Record

Regentis Biomaterials Plans European Surgeon Training for GelrinC Rollout

Regentis Biomaterials announces European surgeon training for GelrinC, a CE Mark-approved cell-free knee cartilage implant, starting Q3 2026 at Humanitas Research Hospital in Milan.

This news matters because it signals a major step toward bringing a novel, cell-free knee cartilage treatment to market in Europe. For patients, GelrinC could offer a less invasive, single-step procedure that avoids the complexities of cell-based therapies. For orthopedic surgeons, the training program ensures they are equipped to deliver this advanced treatment effectively. For investors, the commercialization progress highlights Regentis’ potential to capture a significant share of the knee cartilage repair market, which currently lacks off-the-shelf options.